Suppr超能文献

T4NxM1期肾细胞癌的减瘤性肾切除术:MD安德森癌症中心的经验

Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.

作者信息

Kassouf Wassim, Sanchez-Ortiz Ricardo, Tamboli Pheroze, Jonasch Eric, Merchant Madhur M, Spiess Philippe E, Wood Christopher G

机构信息

Department of Urology, McGill University Health Center, Montreal, Quebec, Canada.

出版信息

Urology. 2007 May;69(5):835-8. doi: 10.1016/j.urology.2007.01.034.

Abstract

OBJECTIVES

Although cytoreductive nephrectomy may provide a survival benefit in metastatic renal cell carcinoma, patients with locally advanced lesions may be denied cytoreduction because of a perceived worse outcome and increased morbidity. We reviewed our experience with cytoreductive nephrectomy in patients with contiguous organ involvement (Stage T4NxM1) to evaluate the outcome and morbidity.

METHODS

From 1993 to 2004, 498 patients underwent cytoreductive nephrectomy for renal cell carcinoma. Of those, 23 patients had Stage T4NxM1 disease. The analyzed variables included surgical complications, palliation of symptoms, and survival.

RESULTS

The median patient age was 55 years (range 35 to 73), with a median tumor size of 15 cm (range 7 to 30). The median overall and disease-specific survival was 6.8 months (range 1.4 to 25.7). The distribution of the histologic type was conventional in 16, papillary in 2, and unclassified in 5. Sarcomatoid features were present in 9 patients. In 2 patients, surgery was aborted because of unresectable disease. Three patients developed postoperative complications (one wound dehiscence, one pancreatic collection, and one seizure). The median length of stay was 7 days (range 5 to 19). Of the 7 patients with local symptoms, 5 experienced postoperative palliation. Most patients (79%) received postoperative systemic therapy after a median of 39 days (range 24 to 114). Five patients did not receive systemic therapy because of disease progression. The median disease-specific survival for the patients who received systemic therapy was 7.1 months (range 1.4 to 25.7), but only 2.5 months (range 0 to 5.2) for those who had not (P = 0.003).

CONCLUSIONS

Cytoreductive nephrectomy in Stage T4NxM1 renal cell carcinoma is feasible and provides significant palliation in symptomatic patients; however, the survival benefit is unclear. Our retrospective series has demonstrated that the prognosis in these patients is poor.

摘要

目的

尽管减瘤性肾切除术可能会给转移性肾细胞癌患者带来生存益处,但局部晚期病变患者可能因预期预后较差和发病率增加而无法接受减瘤手术。我们回顾了我们对累及毗邻器官(T4NxM1期)患者进行减瘤性肾切除术的经验,以评估其疗效和发病率。

方法

1993年至2004年,498例患者因肾细胞癌接受了减瘤性肾切除术。其中,23例患者患有T4NxM1期疾病。分析的变量包括手术并发症、症状缓解情况和生存率。

结果

患者中位年龄为55岁(范围35至73岁),肿瘤中位大小为15 cm(范围7至30 cm)。总体和疾病特异性生存期中位值为6.8个月(范围1.4至25.7个月)。组织学类型分布为:16例为传统型,2例为乳头状,5例未分类。9例患者有肉瘤样特征。2例患者因疾病无法切除而中止手术。3例患者出现术后并发症(1例伤口裂开、1例胰腺积液和1例癫痫发作)。住院时间中位值为7天(范围5至19天)。7例有局部症状的患者中,5例术后症状得到缓解。大多数患者(79%)在中位时间39天(范围24至114天)后接受了术后全身治疗。5例患者因疾病进展未接受全身治疗。接受全身治疗的患者疾病特异性生存期中位值为7.1个月(范围1.4至25.7个月),未接受全身治疗的患者仅为2.5个月(范围0至5.2个月)(P = 0.003)。

结论

T4NxM1期肾细胞癌的减瘤性肾切除术是可行的,对有症状的患者有显著的症状缓解作用;然而,生存获益尚不清楚。我们的回顾性系列研究表明,这些患者的预后较差。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验